logo

US Biopharmaceutical Company Liminatus Pharma Plans to Raise $500 Million to Invest in BNB

By: theblockbeats.news|2025/07/28 12:12:26

BlockBeats News, July 28th, According to a report by businessinsider, Clinical-stage biopharmaceutical company Liminatus Pharma, Inc. (NASDAQ: LIMN) today announced plans to strategically expand into the cryptocurrency and blockchain space.

The company plans to establish a subsidiary named "American BNB Strategy" to lead its digital asset investment and management plan. Through this platform, Liminatus plans to gradually raise and deploy up to $500 million in funds, with the goal of strategically long-term investing in BNB.

Liminatus emphasized that while the company remains fully committed to its core business - advancing cancer treatments and pancreatic cancer diagnostic technologies, expanding into the digital asset space is seen as a necessary step to support long-term growth and enhance shareholder value.

Liminatus is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer patients. The company is advancing a series of novel therapies targeting cancer antigens and tumor-specific immune responses.

Japanese nail art chain Convano has announced another round of funding of 1.5 billion yen to increase its BTC holdings.
The DePIN Project Starpower will take an airdrop snapshot on August 4th at 8:00 AM.

You may also like

Share
copy

Gainers

Latest Crypto News

12:15

Cysic Foundation: Airdrop Eligibility Check Tool Now Live

11:45

WSJ: Investors are Wary of a New Round of the "Crypto Winter"

11:45

Aethir Releases 12-Month Future Roadmap to Accelerate Growth in Global Enterprise AI Computing Business

11:15

24-hour Spot Funding Inflow/Outflow List: ETH Net Outflow of $126 million, ZEC Net Outflow of $18.2 million

11:15

Bloomberg: Fed Never So Split on Long Rate Strategy

Read more
Community
icon
icon
icon
icon
icon
icon
icon

Customer Support@weikecs

Business Cooperation@weikecs

Quant Trading & MMbd@weex.com

VIP Servicessupport@weex.com